Thailand is starting the clinical stage for its
“We hope that the vaccine could generate neutralizing antibodies in humans seen in monkeys and mice,”
The Thai study will begin its human trials as early as September and will be among the first done outside high-income countries. Globally, 160 vaccines are being studied for Covid-19, of which 21 are at the clinical evaluation stage, according to the
Access to life-saving vaccines is a
The first stage of Thai clinical trials will enroll about 100 volunteers separated in two groups, one for people aged 18 to 60 and the other for 60- to 80-year-olds, Kiat said. The focus of the first stage, which will take about two months, is on determining the safety and appropriate dosage for human use. The recruitment for volunteers is expected to start in September.
The second stage, likely to begin in December, will involve 500 to 1,000 people. The vaccine may get emergency-use authorization from the Food and Drug Administration and skip the third and final stage, which would use more than 10,000 volunteers in countries with an ongoing outbreak, according to Kiat.
The Chulalongkorn University vaccine employs new mRNA technology that’s similar to that of a project led by Cambridge, Massachusetts-based
The production of 10,000 doses for the vaccine trials will start next week. Once the trials have completed all stages, Thailand will start output, with the potential to boost supplies for distribution to neighboring nations and other low- or middle-income economies.
To contact the reporter on this story:
To contact the editors responsible for this story:
Stanley James, Paul Geitner
© 2020 Bloomberg L.P. All rights reserved. Used with permission.